# InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

> **NCT04442178** · PHASE2 · TERMINATED · sponsor: **Revimmune** · enrollment: 26 (actual)

## Conditions studied

- COVID-19
- Lymphocytopenia

## Interventions

- **DRUG:** CYT107
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04442178
- **Lead sponsor:** Revimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-15
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** POOR ACCRUAL
- **Last updated:** 2022-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442178, "InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04442178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*